Trial Profile
A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Verteporfin
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms ANCHOR
- Sponsors Genentech
- 14 Feb 2017 New trial record